BiotechTube

100mg SPN-812 + Placebo

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Attention-Deficit/Hyperactivity Disorder

Conditions

Attention-Deficit/Hyperactivity Disorder

Trial Timeline

Mar 19, 2024 → Jun 1, 2026

NCT ID
NCT04781140

About 100mg SPN-812 + Placebo

100mg SPN-812 + Placebo is a approved stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04781140. Target conditions include Attention-Deficit/Hyperactivity Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04781140ApprovedRecruiting

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
ABT-089 + atomoxetine + placeboAbbViePhase 2
52
ABT-089 + PlaceboAbbViePhase 2
52
ABT-089AbbViePhase 2
52
ABT-089 + placeboAbbViePhase 2
52
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
52
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
85
SPN-812Supernus PharmaceuticalsApproved
80
IR Viloxazine + PlaceboSupernus PharmaceuticalsPhase 1/2
36
SPN-812Supernus PharmaceuticalsApproved
80
SPN-812Supernus PharmaceuticalsPhase 3
72
Placebo + SPN-812Supernus PharmaceuticalsPhase 3
72
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812Supernus PharmaceuticalsPhase 2
47
SPN-812Supernus PharmaceuticalsPhase 3
72
TD-9855 + TD-9855 + PlaceboTheravance BiopharmaPhase 2
47

Other Products from Supernus Pharmaceuticals

ZULRESSO®Approved
80
APOKYNApproved
80
SPN-812Approved
80
SPN-812Approved
80
SPN-538 + PlaceboApproved
80